Abstract
Granule cell dispersion (GCD) is a common pathological feature observed in the hippocampus of patients with Mesial Temporal Lobe Epilepsy (MTLE). Pathomechanisms underlying GCD remain to be elucidated, but one hypothesis proposes aberrant reactivation of neurodevelopmental migratory pathways, possibly triggered by febrile seizures. This study aims to compare the proteomes of basal and dispersed granule cells in the hippocampus of eight MTLE patients with GCD to identify proteins that may mediate GCD in MTLE. Quantitative proteomics identified 1,882 proteins, of which 29% were found in basal granule cells only, 17% in dispersed only and 54% in both samples. Bioinformatics analyses revealed upregulated proteins in dispersed samples were involved in developmental cellular migratory processes, including cytoskeletal remodeling, axon guidance and signaling by Ras homologous (Rho) family of GTPases (P < 0.01). The expression of two Rho GTPases, RhoA and Rac1, was subsequently explored in immunohistochemical and in situ hybridization studies involving eighteen MTLE cases with or without GCD, and three normal post mortem cases. In cases with GCD, most dispersed granule cells in the outer-granular and molecular layers have an elongated soma and bipolar processes, with intense RhoA immunolabeling at opposite poles of the cell soma, while most granule cells in the basal granule cell layer were devoid of RhoA. A higher percentage of cells expressing RhoA was observed in cases with GCD than without GCD (P < 0.004). In GCD cases, the percentage of cells expressing RhoA was significantly higher in the inner molecular layer than the granule cell layer (P < 0.026), supporting proteomic findings. In situ hybridization studies using probes against RHOA and RAC1 mRNAs revealed fine peri- and nuclear puncta in granule cells of all cases. The density of cells expressing RHOA mRNAs was significantly higher in the inner molecular layer of cases with GCD than without GCD (P = 0.05). In summary, our study has found limited evidence for ongoing adult neurogenesis in the hippocampus of patients with MTLE, but evidence of differential dysmaturation between dispersed and basal granule cells has been demonstrated, and elevated expression of Rho GTPases in dispersed granule cells may contribute to the pathomechanisms underpinning GCD in MTLE.
Introduction
Temporal lobe epilepsy is the most common form of pharmacoresistant epilepsy in adults (Engel, ). Up to 80% of patients with a mesial form of temporal lobe epilepsy (MTLE) have structural abnormalities in the hippocampus (de Tisi et al., ; Blumcke et al., ). Over 60% of patients with MTLE and hippocampal pathologies remained seizure-free for at least a year after surgical resection of the hippocampus as treatment for their epilepsy (de Tisi et al., ; Engel et al., ; Blumcke et al., ), suggesting that the hippocampus is the primary site for epileptogenesis.
Hippocampal Sclerosis ILAE Type 1 (HS Type 1) is the most common pathology observed in patients with pharmacoresistant MTLE, and it is primarily characterized by segmental loss of pyramidal neurons in cornu ammonis subfields CA1, 3, and 4 (Blumcke et al., ). Over half of the MTLE patients with HS Type 1 also have abnormalities affecting dentate granule cells (DGCs) including granule cell dispersion (GCD) and mossy fiber sprouting (Wieser, 2004; Blümcke et al., ; Thom et al., 2010; Da Costa Neves et al., ). In the normal human hippocampus, DGCs are organized into a compact layer of up to ten cells thick or ≤120 μm (Houser, ; Wieser, 2004). In GCD, ectopic DGCs in clusters or rows disperse to the inner and outer molecular layers of the sclerotic hippocampus, widening the granule cell layer to up to 400 μm in thickness (Blümcke et al., ). The presence, severity, and extent of GCD along the hippocampal body is highly variable amongst patients with MTLE (Thom et al., 2010; Blümcke et al., ) and there is no confirmed grading scheme for GCD in MTLE. The exact cause of GCD in human MTLE is unknown; however, animal models of MTLE with or without hippocampal sclerosis have shown that seizures can displace the migration of newly-generated (Parent et al., ; Hester and Danzer, ) and mature DGCs to CA4 and molecular layer (Murphy and Danzer, ; Koyama et al., ; Chai et al., ). Reelin is an extracellular matrix glycoprotein secreted by Cajal-Retzius cells during neurodevelopment to regulate the correct layering of migrating cells (Frotscher, ). Low levels of reelin transcript and protein have been reported in the hippocampus of patients with MTLE (Haas et al., ; Haas and Frotscher, ) and animal models of MTLE (Heinrich et al., ), possibly as a consequence of elevated methylation at the promotor region of RELN (Kobow et al., ) or loss of reelin-synthesizing neurons in hippocampus (Haas et al., ; Orcinha et al., ). The loss of reelin in MTLE is believed to lead to the “over-running” of DGCs into the molecular layer. Past studies have shown that pharmacological inhibition of mammalian target of rapamycin (mTOR) pathway can prevent the development of the mossy fiber sprouting (Buckmaster et al., ) and reduce the severity of GCD in animal models of MTLE (Lee et al., ), suggesting that the mTOR pathway may have a role in the pathomechanisms of these abnormalities. In patients with MTLE, most astroglial cells strongly expressed markers of mTOR signaling activation such as phospho-S6 ribosomal protein in the sclerotic hippocampus, whereas DGCs showed minimal immunohistochemical evidence of mTOR activation (Sha et al., 2012; Sosunov et al., 2012; Liu et al., ). Clinicopathological studies reported that the presence of GCD in patients with MTLE was associated with a history of early onset of epilepsy and febrile seizures (<4 years) and longer duration of epilepsy (Lurton et al., ; Blümcke et al., ) suggesting that GCD may be a consequence of seizures or brain trauma acquired during the first decade of life where dentate neurogenesis is still active. Although it is unclear whether the presence of GCD is associated with positive surgical outcomes for patients with pharmacoresistant MTLE based on existing literature (Blümcke et al., ; Thom et al., 2010; Da Costa Neves et al., ), there is supportive evidence from animal studies to show that ectopic DGCs increase hippocampal excitability by having a lower activation threshold, forming excess dendritic axonal connections and receiving more excitatory and fewer inhibitory synaptic inputs than normal cells (Zhan et al., 2010; Murphy and Danzer, ; Althaus et al., ). In patients with MTLE, GCD is often observed in conjunction with mossy fiber sprouting, where mossy fibers of DGCs form excitatory synaptic contact with apical dendrites and spines of neighboring DGCs in the molecular layer (Sutula et al., 1989; Cavazos et al., ), thus potentially creating an internal, pro-epileptogenic circuit.
DGCs are functionally important for cognition and memory since they filter the main inputs into the hippocampus, and propagate signals by innervating pyramidal neurons in CA subfields. Electrophysiological in vivo animal studies have demonstrated that DGCs normally have low-excitability, and only a small, spatially-defined population of DGCs would fire to allow the execution of fine and spatially-complex activities such as pattern separation, novelty detection and spatial discrimination (Kahn et al., ). Stimulated DGCs release vesicles containing glutamate to activate the population firing of interconnected CA3 pyramidal cells (Miles and Wong, ; Scharfman and MacLusky, ). Consequently, many stimulated DGCs would enhance hippocampal excitability, thus increasing the chances of seizures (Overstreet-Wadiche et al., ; Hester and Danzer, ), and reducing the ability to perform fine, spatial discrimination tasks (Kahn et al., ). Silencing DGCs using ontogenetic manipulation can reduce seizure frequency and reverse cognitive impairments in animal models of MTLE (Krook-Magnuson et al., ).
In view of the important role DGCs play in cognition and promoting hyperexcitability, it is important to understand mechanisms and substrates driving abnormal displacement of DGCs in patients with MTLE. The proteome of the human hippocampus has been studied in normal (Edgar et al., ; Föcking et al., ; Koopmans et al., ), and diseased post mortem human brains, including in the context of schizophrenia (Edgar et al., ), Alzheimer’s disease (Edgar et al., ; Sultana et al., 2007; Begcevic et al., ; Hondius et al., ), and non-CNS malignancies (Yang et al., 2004a). In epilepsy, the proteomes of surgically-resected hippocampi from patients with refractory TLE (Czech et al., ; Yang et al., 2004b, 2006; Persike et al., , ; Mériaux et al., ) or temporal cortex (Eun et al., ; He et al., ; Keren-Aviram et al., ) have been studied. Most of these past studies investigated the whole hippocampus rather than specific hippocampal subregions, and information about structural hippocampal pathology was not disclosed in three studies (Czech et al., ; Persike et al., , ). None of the previous human proteomic studies discussed GCD in their samples. We aimed to investigate the proteomes of DGCs located in the basal and dispersed regions of the granule and molecular layers of patients with HS Type 1 and GCD, and to identify the molecular substrates that mediate GCD. Ectopic DGCs are potential substrates for recurrent excitation, and they may be the key to understanding MTLE with hippocampal sclerosis and GCD, and its comorbidities including cognitive and memory impairments.
Materials and Methods
Cases
Patients with refractory MTLE who had undergone surgical resection of the hippocampus as a treatment for their epilepsy between 2005 and 2016 were identified from the records of UCL Epilepsy Society Brain and Tissue Bank (Table 1). All patients provided written informed consent for the use of tissue in research studies in accordance with the Declaration of Helsinki, and the study has obtained ethical approval. Eight cases with age at surgery ranged from 20 to 60 years were submitted to proteomic analysis. All cases had HS Type 1 with marked GCD pathology as confirmed by an experienced neuropathologist.
Table 1
| Age at surgery | Cases | Relevant clinical history under age of 4 years | Age of onset (years) | Antiepileptic medications | Neuro-psychometric findings | DG pathology laterality (other pathology) | Type of studies proteomic (n = 8) RhoA IHC (n = 17) RhoA ISH (n = 10) Rac1 ISH (n = 15) |
|---|---|---|---|---|---|---|---|
| Between 20–30 years | E1 | FS | 13 | Carb, Lam, Lev, Mid, Val | No remarkable cognitive deficits | HS Type 1. Left. GCD. MFS | All studies |
| E20 | FS, meningitis | 12 | Carb | Average intellectual abilities and language functions | HS Type 1. Left. GCD. MFS (TS) | RhoA IHC | |
| E2 | FS | 14 | Carb, Lev, Ox, Val | Weak verbal and recognition functions | HS Type 1. Right. GCD. MFS (TS) | All studies | |
| E122 | none | 14 | Carb, Lam, Preg | Weak working and verbal memory | HS Type 1. Right. GCD. MFS. | All except proteomics | |
| E123 | FS | 1.5 | Carb, Lam, Val | Average intellectual abilities and memory. Weak visuospatial processing abilities | HS Type 3 (OH) | All studies except proteomic | |
| E16 | None | 9 | Lam, Lev | Average cognition and memory functions | HS Type 3. Right | Rac1-ISH | |
| E3 | Head trauma | 11 | Carb, Lev, Zon | Weak verbal intelligence and verbal and visual memory | HS Type 1. Left. GCD. MFS | Proteomic, RhoA-IHC | |
| E12 | None | 15 | Lam, Zon | Weak verbal memory | HS Type 3. Left. | Rac1-ISH | |
| Between 31–40 years | E4 | None | 10 | Carb, Lev | Average cognition and memory functions | HS Type 1. Right. GCD. MFS | Proteomic, Rac1-ISH |
| E14 | B cell non-Hodgkin’s lymphoma | 8 | Carb, Lev, Dia | Weak verbal and working memory Depression. Psychosis. | HS Type 1. Left. GCD. MFS | All except proteomics | |
| E13 | FS | 1 | Val, Clob, Carb | Average cognition and memory functions. | HS Type 1. Right. GCD. MFS | All except proteomics | |
| Between 41–50 years | E5P | None | 2 | Lev, Carb | Weak visual memory | HS Type 3. Right. | All except proteomic |
| E11 | None | 8 | Clonazepam, Ox | Weak cognition and visual memory. Depression, Paranoia | HS Type 1. Right. GCD. MFS | All except proteomics | |
| Between 51–60 years | E5 | Head trauma | 16 | Carb, Lam, Pheny | Weak verbal intelligence and working memory. Anxiety. Depression | HS Type 1. Right. GCD. MFS | Proteomic |
| E6 | FS | Late 30s | Carb, Ox, Lev, Lam, Pheno | Weak verbal and non-verbal memory. Psychosis | HS Type 1. Left. GCD. MFS. | All except RhoA-ISH | |
| E7 | n/a | 11 | Val, Preg, Carb | Weak verbal memory and spatial recognition. Paranoia | HS Type 1. Left. GCD. MFS | All studies | |
| E1P | FS | 22 | Carb, Clob | Impaired intellectual ability and visual and verbal memory | HS Type 1. Left. GCD. MFS | All except proteomic | |
| E8 | Head trauma | 8 | Carb, Gaba, Lam, Prim | Poor verbal memory | HS Type 1. Left. GCD. MFS | All studies | |
| 29 | PM44 | COD: sudden death | n/a | None | None | None | RhoA-IHC, qualitative only |
| 35 | PM45 | COD: cardiac arrest | n/a | None | None | None | RhoA-IHC, qualitative only |
| 57 | PM46 | COD: no notes available | n/a | None | None | None | RhoA-IHC, qualitative only |
Clinical details of cases studied.
Eight cases with Hippocampal Sclerosis Type I [according to the International League Against Epilepsy (ILAE) classification system] and granule cell dispersion were analyzed using proteomics (E1–8, in gray). In addition to these cases, another ten surgical cases with MTLE and three post mortem normal cases were included in RhoA and Rac1 immunohistochemical and/or in situ hybridization studies. In situ hybridization studies using probes against CDC42, or RELN transcripts were performed on four cases (E1P, E122, E1, E3). Abbreviations: Carb, carbamazepine; COD, cause of death; Clob, clobazam; Dia, diazepam; Gaba, Gabapentin; GCD, granule cell dispersion; GG, ganglioglioma; HS, hippocampal sclerosis; Lam, Lamotrigine; Lev, Levetiracetam; MCD, malformation of cortical development; MFS, mossy fiber sprouting; OH, oligodendroglial hyperplasia in white matter; Ox, Oxcarbazepine; Pheny, Phenytoin; Pheno, Phenobarbitone; Preg, Pregabalin; Prim, Primidone; TS, temporal sclerosis; Tem, temapazem; Top, topiramate; Val, Sodium valproate; Zon, Zonisamide.
At the initial neuropathological assessment, two 5 mm-thick blocks from each case were coronally sampled from the middle of the hippocampus (2 cm from anterior tip) to ensure that the dentate gyrus was presented for assessment and subsequent experiments. One block of the sampled hippocampus was snap-frozen in liquid nitrogen, stored in −70 freezers and later retrieved for proteomic studies, while the other block was fixed in 10% neutral-buffered formalin, processed and embedded in paraffin wax for histological staining and immunohistochemistry.
Laser Capture Microdissection
Fourteen sections of 14 μm thickness were sectioned from each frozen hippocampal sample, and sections were collected onto polyethylene terephthalate metal frame slides for laser capture microdissection (Leica, Milton Keynes, UK). Two additional sections were collected onto a microscopic slide (VWR International, UK) and stained briefly in 0.1% toluidine blue (pH 4.5) solution for 5 s to visualize the granule cell layer. Laser capture microdissection (LCM 700; Leica, Milton Keynes, UK) was then carried out along the entire length of the GCL of multiple sections per case to capture basal and dispersed DGCs (Figure 2A). Basal samples included DGCs in the granule cell layer closest to CA4, while the dispersed samples included ectopic DGCs in the outer-granular layer and inner and outer molecular layers. A total tissue area of 9 ± 1 mm2 was dissected for each case, and submitted for proteomic analysis.
Figure 1
Figure 2

Bioinformatics analyses. (A) An image of a toluidine-stained hippocampal tissue section showing marked granule cell dispersion pathology (top). DGCs were extracted from frozen hippocampal tissue sections during laser microdissection. Extracted DGCs (including nuclei and ~10 μm-perinuclear rim as cytoplasm) were divided into either basal or dispersed samples per case based on their location within the dentate gyrus. Basal samples contained DGCs located in the basal layer of the granule cell layer (black outline). These round DGCs were closely situated to neighboring DGCs, and they were aligned along the border of CA4 and granule cell layer. Dispersed samples contained a mixture of round and elongated DGCs located ectopically, in rows or clusters in the outer-granular, inner and outer molecular layers (green outline). Individual, small, round nuclei scattered in the dentate gyrus, sometimes in close proximity to DGCs, were likely to glial cells, and therefore these cells were avoided where possible. (B) Finding from proteomic studies show that more than 50% of the identified proteins were shared between basal and dispersed samples and between younger (<35 years) and older cohorts (<50 years). Less than one-third of the identified proteins were uniquely detected in basal, dispersed, younger and older samples. (C) A dendrogram showing hierarchical clustering of all differentially expressed proteins in eight MTLE cases with GCD. The pattern of protein changes between dispersed and basal samples was more similar between cases E1 and E2 (younger cohort) and E5, E6, and E8 (older cohort). (D) Heat map showing logarithmic-2 fold change between dispersed and basal samples (D/B), or younger and older cohorts (Y/O) of selected proteins expressed in neuronal (MAP2, calbindin, calretinin), glial (GFAP, S100-B, MBP, connexion 43), vascular (VEGFR), immature cell (vimentin) and proliferative populations (MCM2, MCM4, PCNA, cyclin B3), or are proteins associated with cytoskeletal (profiling-1, alpha-synuclein, f-actin capping protein, DPYL2, stathmin) and synapse remodeling (synaptotagmin-1, synapsin-2), mTOR pathway (PS6, PS6 kinase), neurogenic niches (NCAM1, CADM2), vascular changes (carbonic anhydrase 1, hemoglobin) and inflammation (C1QBP, HSP70). Keys: * or ∧ significantly overexpressed proteins (P < 0.05), **proteins found in dispersed samples of GCD cases only, ***proteins found in basal samples of GCD cases only, ∧∧proteins only found in younger cohort only, ∧∧∧proteins found in older cohort only. Abbreviations: C1QBP, complement component 1Q subcomponent-binding protein; DPYL2, dihydropyrimidinase-related protein 2; GFAP, glial fibrillary acidic protein; HSP70, heat shock proteins; MAP2, microtubule-associated protein 2; MBP myelin binding protein; MCM2, minichromosomal maintenance 2; NCAM1, neural cell adhesion molecule 1; PCNA, proliferating cell nuclear antigen; PS6 ribosomal protein S6; VEGFR vascular endothelial growth factor receptors. (E,H) Volcano plots showing logarithmic-2 fold change against –log P-value for proteins that were expressed in both dispersed and basal samples (E) or in both younger and older cohorts (H). Significantly differentially expressed proteins that showed over the 1.5-fold change were highlighted in the plots (P < 0.05). (F,G) The abundance of each protein was compared between basal and dispersed samples, and between younger and older cohorts. Proteins that were uniquely expressed in one group only, and proteins that were significantly expressed by 1.5-fold than comparative group (fold change >1.5, P < 0.05) generated the Dispersed, Basal, Younger and Older clusters. Each cluster was submitted to bioinformatics platforms for Gene Ontology and Pathways analyses. Top functional annotation clusters based on Gene Ontology, Uniprot keywords, and sequences and INTERPRO terms for proteins in the Dispersed (F) and Basal clusters (G) were listed (P < 0.01; also refer to Supplementary Material S3). The enrichment scores generated by bioinformatics platforms and the percentage of proteins submitted that were associated with each functional annotation cluster are illustrated. Network maps show the connections between proteins in small GTPase mediated signal transduction (F) and ribosomes annotation clusters (G). (I,J) Proteins in the Dispersed and Basal clusters were significantly involved in a number of pathways (P < 0.01; also refer to Supplementary Material S4). The size of the circle represents the number of proteins submitted that were involved in the pathways. The thickness of connections refers to the number of proteins that belongs to both connecting pathways.
Proteomic and Bioinformatics Analyses
Samples were denatured using in-solution trypsin digestion and prepared for MSe label-free quantitative proteomics as described previously (Heywood et al.,
Other clinical details, including patients’ epilepsy history and psychometry, were also reviewed and analyzed with proteomic data. Pre-operative MRI sequences, PET, EEG, video-telemetry, and psychometry had been carried out according to the epilepsy surgical protocols at the National Hospital of Neurology and Neurosurgery, and clinical findings were reviewed for each case.
Immunohistochemistry
Eighteen cases were included in RhoA, Rac1, and Cdc42 immunohistochemistry and/or in situ hybridization studies. Cases included eight MTLE cases submitted for proteomics, an additional six surgical MTLE with hippocampal sclerosis and GCD, four surgical MTLE with hippocampal sclerosis but no GCD, and three postmortem healthy controls (Table 1).
Five micrometer-thick formalin-fixed, paraffin-embedded sections from selected cases were examined histologically with Haematoxylin and Eosin, and Luxol Fast Blue stains. Routine automated and manual immunochemistry was performed using antibodies against neuronal nuclei (NeuN), glial fibrillary acidic protein (GFAP), non/phosphorylated neurofilament (SMI32, SMI31), myelin basic protein (SMI94), microtubule associated protein 2 (MAP2), zinc transporter 3 (ZnT3) calbindin, nestin (Table 2). Additional immunohistochemistry using anti-RhoA was performed manually using pretreatment and incubation procedures described in Table 2, and breast carcinoma tissue was used as a positive control (Ma et al.,
Table 2
| Antibodies/Probes Clone, Code | Immunogen or target epitope | Labeled cell or protein type | Pre-treatment (mins) | Antibody supplier, dilution, incubation time (mins) and temperature |
|---|---|---|---|---|
| Anti-NeuN A60, MAB377 | Purified cell nuclei from mouse brain | Nuclei of most neurons, some proximal dendrites | ER1 (20) | Millipore; 1:2K, 15, RT |
| SMI31 801601 | Phosphorylated epitope in neurofilament H and M | Neurons | H-3301 (12) | Sternberger; 1:500, ov, 4°C |
| SMI32 801707 | Non-phosphorylated epitope in neurofilament H | Neurons | H-3301 (12) | Sternberger; 1:500, ov, 4°C |
| Anti-MAP2 HM-2, M4403 | Rat microtubule-associated proteins | Neurons | H-3301 (12) | Sigma; 1:1,500, ov, 4°C |
| Anti-Calbindin D-28K, 300 | Calbindin D-28k | Calbindin-expressing interneurons | H-3301 (12) | Swant; 1:10K, ov, 4°C |
| Anti-ZnT3 197–003 | Recombinant protein of mouse ZnT3 (aa. 2–75) | Synaptic vesicle located zinc-transporter | H-3301 (12) | Synaptic Systems; 1:10K, ov, 4°C |
| SMI 94 SMI-94R | 70–89 aa of human myelin basic protein | Myelinated fiber in white matter | ENZ1 (10) | DAKO; 1:2,000, 20, RT |
| Anti-Nestin 10C2, AB22035 | 150 aa recombinant fragment from human nestin conjugated to GST | Immature progenitors, glia, endothelial cells | H-3301 (12) | Abcam; 1:1K, ov, 4°C |
| Anti-GFAP Z0334 | GFAP isolated from cow spinal cord | Astrocytes, some ependymal cells | ENZ1 (10) | DAKO; 1:2.5K, 20, RT |
| Anti-RhoA OSR00266W | A synthetic peptide from human Transforming protein RhoA conjugated to an immunogenic carrier protein | Small GTPase protein that regulates actin cytoskeleton in the formation of stress fibers, and cell division. Expressed in the cytoplasm of cells undergoing structural changes in preparation for migration | Protease (20, 37°C) | Thermo; 1:500, ov, 4°C |
| RHOA mRNA 416291 | NM_001664.2. Probe region from 135 to 1796 | Pretreatment 2 and 3* | BioTechne; 120, 40°C | |
| RAC1 mRNA 419851 | NM_006908.4 Probe region from 1194 to 2256 | Pretreatment 2 and 3* | BioTechne; 120, 40°C | |
| CDC42 mRNA 502651 | NM_044472.2 Probe region from 2 to 1091 | Pretreatment 2 and 3* | BioTechne; 120, 40°C | |
| RELN mRNA 413051 | NM_173054.2 Probe region from 4401 to 5340 | Glycoprotein expressed by Cajal-Retzius cells | Pretreatment 2 and 3* | BioTechne; 120, 40°C |
Antibodies and protocols for RNA and immunohistochemical studies.
Automated immunohistochemistry was performed using the Bond Max automated immunostainer and reagents (Leica, Milton Keynes, UK). *RNA detection was performed using the RNAscope patent assays system following the supplier’s instruction. Abbreviations: aa, amino acids; Cdc42, Cell division control protein 42 homolog; GFAP, glial fibrillary acidic protein; K, thousands; MAP, microtubule-associated protein; NeuN, neuronal nuclei; ov, overnight; Rac1, Ras-Related C3 Botulinum Toxin Substrate 1; RhoA, Transforming protein RhoA or Ras homolog family member A; RT, room temperature. Antigen retrieval buffers: ENZ1, Leica Bond enzyme concentrate, and diluent; ER1, Leica Bond citrate-based buffer; ER2, Leica Bond EDTA-based buffer; H-3301, Vector’s Tris-based buffer pH 9.0; H-3300, Vector’s citrate-based buffer pH 6.0; SC, Sodium citrate buffer, pH 6.0. Suppliers: Abcam plc., Cambridge, UK; BD Transduction Lab., Oxford, UK; Bio-Techne, Abingdon, UK; DAKO, Cambridgeshire, UK; Millipore, Watford, UK; Sternberger, Maryland, US; Swant, Marly, Switzerland; Thermo Fisher Scientific, Hemel Hempstead, UK; Synaptic Systems, Goettingen, Germany.
In situ Hybridization
Five micrometer-thick formalin-fixed, paraffin-embedded sections from selected surgical cases were processed for in situ hybridization following supplier’s instructions (Wang et al., 2019). Probes against human RHOA, RAC1, CDC42, and RELN mRNAs were used in conjunction with ready-to-use reagents from RNAscope® 2.5 HD Reagent Brown and Duplex kits (Table 2; Bio-Techne, Abingdon, UK). Positive probe control, UBC, and negative probe control, dapB transcripts, were performed on Hela cell tissue (positive tissue control) and formalin-fixed, paraffin-embedded surgical human brain tissue to ensure specificity of labeling prior to final studies. Labeled sections were counterstained with Gills I hematoxylin solution (VWR, UK) before coverslipped.
Image Analysis
Labeled sections were assessed qualitatively using a brightfield microscope (Nikon Eclipse 80i) and subsequently scanned at 40x magnification using the whole slide scanner, AxioScan.Z1 (Zeiss, Germany) to obtain high-quality digital images for quantitative analysis and data interpretation. All images were viewed and analyzed using the image analysis software, QuPath (Bankhead et al.,
Automated quantification of RhoA immunopositive labeling, and RhoA and Rac1-positive puncta from in situ hybridization studies were performed using QuPath. First, granule cell layer, inner and outer molecular layers spanning 120, 215 and 310 μm from the basal granule cell layer were annotated. The software was then trained to recognize hematoxylin-stained nuclei, positive labeled cells and puncta using positive cell and subcellular detection modules (Bankhead et al.,
Results
Granule Cell Pathology Observed in Cases Submitted for Proteomics
In MTLE cases with GCD, a thick band of NeuN-positive cells was observed in the dentate granule cell layer (Figure 1A). Two morphologies of NeuN-positive DGCs were noted: the basal population of DGCs located closer to CA4 was round and tightly packed with neighboring DGCs (basal DGCs), and a dispersed population of NeuN-positive DGCs with round or elongated soma with uni- or bipolar processes located in outer-granular and molecular layers of the hippocampus (dispersed DGCs). In the case of E6, the bilamination of the granule cell layer was observed, and a gap of approximately 130 μm measured from the bottom of the basal layer to the top of the dispersed layer was noted. No marked difference in NeuN-positive immunolabeling was noted between younger and older cohorts. In contrast, the granule cell layer in the hippocampus of four MTLE cases with no GCD (Figure 1F) and healthy post mortem controls contained round, tightly packed NeuN-positive cells, and no immunopositive cells were observed in the molecular layer. Quantitative measures of granule cell layer revealed a significantly thicker granule cell layer in MTLE cases with GCD than cases without GCD or healthy controls (P = 0.004; mean ± SEM, range; cases with GCD 133 ± 11 μm, 71–213 μm; cases without GCD 64 ± 10 μm, 34–82 μm; healthy controls; 70 ± 4 μm, 63–76 μm).
MAP2-positive cells were observed in the granule cell layer of all MTLE cases (Figures 1B,G). Numerous MAP2-positive processes were observed in the granule and molecular layers. Random short MAP2-positive processes were observed in the CA4 around a few large densely-labeled MAP2-positive cells. Calbindin-positive cells expression was observed in DGCs scattered throughout the outer-granule cell layer and molecular layer of MTLE cases with GCD (Figure 1C). In cases with GCD, calbindin-positive dispersed DGCs had round cell bodies, and occasionally, calbindin-positive cells with long processes extending into the molecular layer were noted. Not all DGCs in the outer-granular layer were calbindin-positive, and the majority of basal DGCs in the sclerotic hippocampus were devoid of calbindin immunolabeling. In contrast, calbindin-positive DGCs were often observed in the granule cell layer of cases without GCD (Figure 1H). ZnT3-positive processes were observed in between DGCs in the granule cell layer and in the molecular layer and CA4 subfield of cases with GCD (Figure 1D). In cases without GCD, ZnT3 immunolabeling was primarily observed in CA4 (Figure 1I). GFAP immunolabeling was observed throughout the hippocampus of all cases, with more intense labeling detected in MTLE cases with GCD (Figure 1E) compared to cases without hippocampal sclerosis or GCD (Figure 1J), and healthy controls. DGCs in the granule cell layer were not immunopositive for GFAP, but GFAP-positive processes extended between DGCs in the granule cell layer, and individual GFAP-positive cells were observed in the molecular layer of cases with GCD. In cases with GCD, a very dense matrix of GFAP processes was observed in the CA4. In contrast, distinctive GFAP-positive cells were seen in the CA4 of cases without GCD (Figure 1J) and in healthy postmortem controls.
Proteomic Analysis
One-thousand eight-hundred and eighty-two proteins were identified in the proteomic analysis of eight patients with HS Type 1 and GCD (Table 1, E1–8). 29% of the extracted proteins were observed in the basal samples only, 17% in the dispersed samples only, and 54% of the proteins were observed in both samples (Figure 2B). 19% of identifiable proteins were observed in the younger cohort only, 28% in older samples only and the remaining proteins were found in both younger and older samples. Some similar changes in protein expression were observed between two cases in the younger cohort (E1 and E2), and amongst three older cases, E5, E6, E8 based on hierarchical clustering (Figure 2C).
Common neuronal markers such as MAP2, calbindin, and calretinin were detected in MTLE samples (Figure 2D). The protein abundance of MAP2, calretinin, and calbindin was significantly higher in dispersed and younger samples than basal and older samples. The quantity of MAP2 detected was higher than calbindin and calretinin in all samples as expected based on earlier immunohistochemical studies (Figures 1B,C). Astroglial (GFAP, vimentin, S100-B) and oligodendroglial markers (Myelin Basic Protein, MBP) were also detected in all samples, consistent with immunohistochemical findings (Figure 1E). The expression of GFAP was comparable between basal and dispersed samples and was slightly higher in younger than older samples; of interest, the expression of vimentin, expressed in immature astrocytes, was predominantly observed in basal and younger samples (Figure 2D) in keeping with our previous studies (Liu et al.,
Volcano plots in Figures 2E,H highlighted the most significantly differentially-expressed proteins between dispersed and basal samples, and between younger and older cohorts respectively. Proteins uniquely expressed in dispersed samples, and proteins significantly displaying over 1.5-fold change in dispersed compared to basal samples (Figure 2E; Supplementary Material S2) were first submitted to gene ontology and pathway bioinformatics analyses (Dispersed cluster, 330 proteins). The top functional annotation clustering based on Gene Ontology, Uniprot keywords, and sequences, and INTERPRO terms were GTP-binding and activity (enrichment score, 10; P = 3.67 × 10−8), cell to cell adhesion (enrichment score, 7; P = 2.61 × 10−6), and small GTPase-mediated signal transduction (enrichment score, 7; P = 5.60 × 10−4); Figure 2F and Supplementary Material S3). Under the functional clustering of small GTPase-mediated signal transduction, a number of proteins in the Ras homolog (Rho) GTPase families such as RhoA, Rac1, Cdc42 and ARGAP1, and ARGAP35 were identified (Table 3 and Supplementary Material S5). Key pathways associated with differential proteins in the Dispersed cluster were related to cellular migration and actin cytoskeletal remodeling, including signaling by Rho GTPases pathway (R-HSA194315; P = 1.02 × 10−6), axon guidance (R-HSA422475; P = 1.25 × 10−6), regulation of actin cytoskeleton (K-HSA04810; P = 1.01 × 10−4), and vesicle-mediated transport (R-HSA5653656, P = 9.29 × 10−7; Figure 2I and Supplementary Material S4). Rho GTPases are small GTPases that regulate cytoskeletal dynamics and cell migration, which maybe of relevance to abnormal migration of DGCs in GCD. The signaling by Rho GTPases pathway shared common proteins with other pathways related to cytoskeletal dynamics as illustrated in Figure 2I. Proteins detected in basal samples only, and proteins that were significantly overexpressed in basal samples by at least 1.5-fold compared to dispersed samples (Figure 2E and Supplementary Material S2) were subsequently submitted to gene ontology and pathway enrichment analyses (Basal cluster; 555 proteins). The top functional annotation clustering included proteins involved in ribosomes, translation and RNA processing (enrichment score, 18; P = 1.79 × 10−14), cell-cell adherens (enrichment score, 10; P = 1.93 × 10−8), GTP binding (enrichment score, 9; P = 4.31 × 10−7), ubiquitin-protein ligase activity (enrichment score, 4; P = 4.926 × 10−2), and regulation of amino acid metabolic processes and proteasome activity (enrichment score, 3; P = 2.07 × 10−2; Figure 2G and Supplementary Material S3). The interactions between proteins clustered under ribosomes, translation and RNA processing are shown as a network map in Figure 2G. Pathways associated with Basal cluster were predominantly related to metabolism (R-HSA1430728, P = 2.53 × 10−26), including amino acid (WP3925, P = 234 × 10−5) and selenocysteine metabolisms (H-HSA2408557, P = 1.71 × 10−24), and electron transport chain (WP111, P = 4.73 × 10−3), and ribosomes (K-HSA03010, P = 5.00 × 10−13), translational mechanisms (R-HSA156842, P = 2.90 × 10−24), and proteasomal degradation (WP111, P = 4.73 × 10−3; Figure 2J and Supplementary Material S4).
Table 3
| Entry ID | Gene | Protein |
|---|---|---|
| P60953 | CDC42 | Cell division control protein 42 homolog |
| E7EVJ5 | CYFIP2 | Cytoplasmic FMR1-interacting protein 2 |
| Q7L576 | CYFIP1 | Cytoplasmic FMR1-interacting protein 1 |
| F8W7L3 | A2M | Alpha-2-macroglobulin |
| Q12802 | AKAP13 | A-kinase anchor protein 13 |
| H0YE29 | ARHGAP1 | Rho GTPase-activating protein 1 |
| Q9NRY4 | ARHGAP35 | Rho GTPase-activating protein 35 |
| I3L4C2 | BAIAP2 | Brain-specific angiogenesis inhibitor associated protein 2 |
| P11274 | BCR | Breakpoint cluster region protein |
| A0A087X0P0 | CENPE | Kinesin-like protein Dispersed |
| G3XAM7 | CTNNA1 | Catenin-alpha-1 |
| P78352 | DLG4 | Disks large homolog 4 |
| Q99880 | HIST1H2BL | Histone H2B type 1-L |
| Q15691 | MAPRE1 | Microtubule-associated protein RP/EB family member 1 |
| Q9Y2A7 | NCKAP1 | Nck-associated protein 1 |
| Q9NZQ3 | NCKIPSD | NCK-interacting protein with SH3 domain |
| P35080 | PFN2 | Profilin-2 |
| P62140 | PPP1CB | Serine/threonine-protein phosphatase PP1-beta catalytic |
| C9J9C1 | PPP2R1A | Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A |
| P63000 | RAC1 | Ras-related C3 botulinum toxin substrate 1 |
| C9JNR4 | RHOA | Transforming protein RhoA/Ras homologous family member A |
| P62745 | RHOB | Rho-related GTP-binding protein RhoB |
| Q8IXI2 | RHOT1 | Mitochondrial Rho GTPase 1 |
| P31947 | SFN | 14–3–3 protein sigma |
| O43295 | SRGAP3 | SLIT-ROBO Rho GTPase-activating protein 3 |
| A2IDB2 | YWHAH | 14–3–3 protein eta |
Proteins in the Dispersed cluster that were involved in signaling by the Rho GTPases pathway (Reactome, R-HSA194315; P = 4.68 × 10−9).
Immunohistochemical and in situ Hybridization Using Markers Against Rho GTPases
Bioinformatics analyses revealed a number of proteins in the signaling by Rho GTPases pathway either uniquely expressed or upregulated in dispersed samples of MTLE cases with GCD. To further investigate the expression of Rho GTPases, immunohistochemistry and in situ hybridization using antibodies and probes against RhoA, Rac1 and Cdc42 protein and mRNAs respectively were performed on surgical, formalin-fixed, paraffin-embedded, hippocampal tissue from cases submitted to proteomics, and additional surgical MTLE cases with or without GCD. Post mortem hippocampal tissue from three healthy donors was also included for qualitative assessment.
In cases without GCD, the majority of DGCs in the granule cell layer were immunonegative for RhoA (Figures 3A,A′). In contrast, cases with GCD had numerous RhoA-immunopositive DGCs in the outer-granule and molecular layers. RhoA-immunopositive DGCs in the granule cell layer generally had a large, round nucleus surrounded by a thin, perinuclear “ring” of immunopositive labeling, or a “cone” of localized RhoA immunolabeling at one end of the cell soma, usually facing either towards the molecular layer or CA4 region (Figures 3B,3B′,3C,3C′). Occasionally, RhoA-positive cells in single-chain formation near vascular structures were observed (Figures 3C,C′). Most RhoA-positive cells in the molecular layer had an elongated cell soma with protruding uni- or bipolar processes. In a case with a bilaminar granule cell layer (E6), most DGCs in the basal granule cell layer were devoid of RhoA immunolabeling (Figure 3D), while most DGCs in the second granule cell layer had distinct RhoA immunoreactivities in one or bipolar ends of the cell soma (Figures 3D′,D″). Quantitative studies revealed a significantly higher density of RhoA-positive cells and a higher percentage of cells expressing RhoA in the granule and molecular layer of MTLE cases with GCD than without GCD (mean ± s.e.m; GCL, GCD 44 ± 3%, no GCD 23 ± 6%, P = 0.035; IML, GCD 56 ± 3%, no GCD 14 ± 3%, P = 0.001; OML GCD 27 ± 5%, no GCD 10 ± 3%, P = 0.008; Figure 3E and data in Supplementary Material S6). In cases with GCD, a higher percentage of cells expressing RhoA were detected in the inner molecular cell layer than the granule cell layer and the outer molecular layer (IML-GCL, P = 0.026; IML-OML, P = 0.003; Figure 3E). In contrast, the percentage of RhoA-positive cells detected were not significantly different between regions in cases without GCD. No significant difference in density or percentage of cells expressing RhoA was noted between younger and older cohorts. A probable relationship was observed between the percentage of cells expressing RhoA and age of surgery (rs = 0.390, P = 0.014; Figure 3F), and the mean thickness of granule cell layer (rs = 0.675, P < 0.001; Figure 3G).
Figure 3

RhoA immunohistochemical studies. (A) Most DGCs were immunonegative for RhoA in the granule cell layer of an MTLE case without GCD (E5P). Occasionally, weak perinuclear RhoA-positive labeling was observed in a few DGCs (A’, higher magnification of area outlined inA). No DGCs were observed in the molecular layer of cases without GCD. (B,C) Numerous DGCs with intense RhoA immunolabeling were observed in the granule and molecular cell layer of two MTLE cases with GCD (E14, B; E3, C). In some DGCs, RhoA immunolabeling was detected in one polar end of the DGC soma directed towards the CA4 or molecular layer. A number of RhoA-positive cells in the outer-granular and molecule layer had elongated soma with uni- or bipolar processes (B’,C’). In bipolar DGCs, RhoA immunolabeling was observed at one or both apices of cell soma. Occasionally, RhoA-positive DGCs were found to align single line formation near blood vessels (C’). In contrast, most basal DGCs closest to the CA4 border had no or minimal RhoA immunolabeling. (D) Bilamination of the granule cell layer was observed in a case with MTLE and GCD E6. In this case, most DGCs in the basal granule cell layer appeared to be devoid of RhoA immunolabeling. In contrast, nearly all DGCs in the outer-granule layer (D’) and second granule cell layer expressed RhoA (D”) either in one or both ends of the cell. The majority of RhoA-positive cells in the second granule cell layer had stronger and distinct RhoA immunoreactivities at the end directed towards the molecular layer. (E) A boxplot showing that the percentage of cells with RhoA-positive labeling in the dentate gyrus of MTLE cases with GCD (blue) or without GCD (red). A significantly higher percentage of cells expressing RhoA was observed in granule and molecular layers of cases with GCD than cases without GCD (GCL, P = 0.035; IML, P = 0.001; OML, P = 0.008; see Supplementary Material S6). In cases with GCD, the percentage of cells with RhoA immunolabeling was significantly higher in the inner molecular layer than the granule cell (P = 0.026) and outer molecular layer (P = 0.003). (F,G) The percentage of cells expressing RhoA in the dentate gyrus weakly correlated with the age at surgery of MTLE patients (rs = 0.390, P = 0.014; F) and the mean thickness of granule cell layer (rs = 0.675, P < 0.001; G). Abbreviations: DG, dentate gyrus; GCL, granule cell layer; IML, inner molecular layer; OML, outer molecular layer. Scale bars, 50 μm. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
In situ hybridization studies using probes against RHOA and RAC1 mRNA sequences revealed fine nuclear and perinuclear puncta in DGCs in the granule and molecular layers of all cases (Figures 4A–D). RHOA-positive and RAC1-positive puncta were also observed in the neuropil, likely representing processes of DGC which were not visible in the sections. In cases with GCD, a high number of RHOA-positive and RAC1-positive puncta clustered at the polar ends of the DGC soma, particularly in DGCs situated in the molecular layer (Figures 4B,D). Some smaller hematoxylin-stained glial cells were associated with none or only a few numbers of RHOA-positive or RAC1-positive puncta. Further immunohistochemical and in situ hybridization double-label studies showed that glutamine synthetase-labeled astrocytes did not have RHOA-positive or RAC1-positive puncta (Supplementary Material S7).
Figure 4

RHOA and RAC1 in situ hybridization studies. (A–D)RHOA and RAC1-positive puncta (cyan) were observed in the dentate gyrus of MTLE cases without GCD (A,C) and cases with GCD (B,D). The majority of positive puncta were found in or around hematoxylin-stained nuclei (purple) in the granule and molecular cell layers. In MTLE cases with GCD, most RHOA and RAC1-positive puncta were localized peri-nuclearly and at opposite ends of each nucleus (B,D). Many RAC1-positive puncta were also observed in the proximal portion of uni- or bipolar processes (D). A number of RHOA and RAC1-positive puncta were also observed in the neuropil. (E,G) In cases without GCD, the density of cells with RHOA and RAC1-positive puncta was higher in the granule cell layer than inner (RHOAP = 0.023; RAC1P = 0.001) and outer molecular layer (RHOAP = 0.004; RAC1 P = 0.018). In cases with GCD, significantly higher densities of cells with RHOA and RAC1-positive puncta were observed in the granule than outer molecular layers (RHOAP = 0.004; RAC1P = 0.017), but not in the inner molecular layer (P > 0.05). The density of cells expressing RHOA mRNAs in the inner molecular layer was significantly higher in cases with GCD than cases without GCD (P = 0.05), but this difference was not observed in the granule cell layer or outer molecular layer (P > 0.05). (F,H) The percentage of cells with RHOA or RAC1-positive puncta weakly correlated with age of onset in patients with GCD (RHOA, rs = 0.439, P = 0.011; RAC1, rs = 0.295, P = 0.049), but not in patients without GCD. Abbreviations: DG, dentate gyrus; GCL, granule cell layer; IML, inner molecular layer; OML, outer molecular layer. Scale bars, 50 μm. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Quantitative analyses showed that a higher density of cells with RAC1-positive puncta than RHOA was observed in MTLE with GCD (mean ± SEM, RAC1 2.05 × 10−3 ± 2.15 × 10−4 per μm2; RHOA 1.74 × 10−3 ± 2.71 × 10−4; P = 0.017), which was not observed in cases without GCD (RAC1 1.72 × 10−3 ± 2.27 × 10−4 per μm2; RHOA 1.25 × 10−3 ± 1.81 × 10−4; P > 0.05). In all cases, a significantly higher density of cells with RHOA-positive puncta was observed in the granule cell layer than outer molecular layer (GCD, GCL 2.83 × 10−3 ± 5.61 × 10−4 per μm2, OML 8.97 × 10−4 ± 1.01 × 10−4, P = 0.004 (blue bars); no GCD, GCL 2.11 × 10−3 ± 2.23 × 10−4 per μm2, OML 7.24 × 10−4 ± 6.94 × 10−5, P = 0.004 (red bars); Figure 4E and Supplementary Material S6). A significantly higher density of RHOA-positive puncta was observed in the granule cell layer than inner molecular layer in cases without GCD (GCL 2.11 × 10−3 ± 2.23 × 10−4 per μm2, IML 9.25 × 10−4 ± 9.15 × 10−5, P = 0.023), but not in cases with GCD (GCL 2.83 × 10−3 ± 5.61 × 10−4 per μm2, IML 1.49 × 10−3 ± 1.84 × 10−4, P > 0.05), indicating that the level of RHOA gene expression was more similar between granule and inner molecular layers in cases with GCD than in cases without GCD. A significantly higher density of RHOA-positive puncta was observed in the inner molecular layer of cases with GCD than without GCD (GCL 1.49 × 10−3 ± 1.84 × 10−4 per μm2 IML; no GCD IML 9.25 × 10−4 ± 9.15 × 10−5, P = 0.05). In all cases, the densities of cells with RAC1-positive puncta were higher in granule cell layer than the outer molecular layer (GCD, 3.31 × 10−3 ± 4.47 × 10−4 per μm2 GCL, 1.14 × 103 ± 1.24 × 10−4 OML, P = 0.017; no GCD, 2.92 × 10−3 ± 3.47 × 10−4 per μm2 GCL, 1.01 × 10−4 ± 8.99 × 10−5 OML, P = 0.018, Figure 4G). A significantly higher density of RAC1-positive puncta was noted in the granule cell later compared to inner molecular layer in cases without GCD (GCL 2.92 × 10−3 ± 3.47 × 10−4 per μm2, IML 1.23 × 10−3 ± 1.62 × 10−4, P = 0.001), but not in cases with GCD (GCL 3.31 × 10−3 ± 4.47 × 10−4 per μm2, IML 1.70 × 10−3 ± 2.06 × 10−4, P > 0.05). The percentage of cells with RHOA-positive and RAC1-positive puncta weakly correlate with the age of onset (RHOA, rs = 0.439, P = 0.011, Figure 4F; RAC1, rs = 0.294, p = 0.049, Figure 4H).
In situ hybridization using probes against CDC42 and RELN mRNAs were also performed on surgical cases, and labeling was qualitatively assessed as only four cases were investigated. The regional distribution and density of cells with CDC42-positive puncta were similar to RHOA-positive and RAC1-positive positive labeling. RELN-positive puncta were not observed in any of these cases.
Discussion
We investigated the proteome of basal and dispersed DGCs in the dentate gyrus of pharmacoresistant MTLE patients with hippocampal sclerosis to explore the neurodevelopmental pathomechanisms of GCD. We have identified differences in the proteomes between basal and dispersed populations of DGCs in the hippocampus of patients with MTLE and GCD. Specifically, dispersed DGCs in cases with GCD highly expressed mature neuronal markers, MAP2, calbindin, and calretinin as well as a number of Rho GTPases and proteins associated with cell migration, cytoskeleton, and synapse remodeling. These results were further supported by findings from immunohistochemical and in situ hybridization studies, where a significantly higher density and percentage of cells expressing RhoA mRNA and protein was observed in the dentate gyrus of cases with GCD than cases without GCD. The expression of RhoA protein was localized to the opposite ends of uni- or bipolar of DGCs in the molecular layer of cases with GCD. Consistently, the mRNAs of RHOA, RAC1, and CDC42 were also found in the same intracellular region of DGCs, while RAC1 mRNA was also detected in the proximal portion of processes. These findings provide evidence supportive of DGCs undergoing neurodevelopment processes relating to cellular migration, which may contribute to the abnormal dispersion of DGCs in patients with MTLE.
Comparison With Previous Human Proteomics Studies
The current study reported on proteins identified from the dentate gyrus of eight patients with refractory MTLE and HS Type I and GCD (or Type II granule cell pathology according to Blümcke et al.,
Our proteomic studies did not include surgical or post mortem healthy controls as seen in most previous human proteomic studies of MTLE. This is because (i) surgically-resected “normal” hippocampal tissue from healthy individuals is not available for research; (ii) the process of protein extraction for proteomic analyses is different for surgical and post mortem brain tissue so one standardized protocol cannot be applied to both type of tissue; and (iii) autopsy tissue is likely to be affected by post mortem processes such as rapid protein degradation (especially for tubulins, intermediate filaments, high motility group box protein-1, proapolioprotein, hemoglobin and mutant derivative (He et al.,
The differential expression of certain proteins in our study is generally consistent with findings from previous human MTLE studies. There is good agreement amongst human TLE proteomics studies that most proteins related to metabolism are significantly upregulated in epilepsy compared to archival normal brain hippocampal samples (Eun et al.,
A key finding in this study is the identification of proteins in dispersed DGCs of cases with GCD specifically involved in axonal guidance (including beta-spectrin, growth-associated protein 43, postsynaptic density protein 95, profilins), regulation of actin cytoskeleton (cytoplasmic FMR1-interacting proteins, WAVE complex proteins), cytoskeletal and synaptic remodeling (DPYL2, alpha-synuclein, synaptotagmin 1, synapsin II, and stathmin1), as well as Rho GTPases, signaling (RhoA, Cdc42, Rac1, brain-specific angiogenesis inhibitor, Rho GTPases activating proteins; Table 3). These processes are active during neurodevelopment and in neurogenic niches in the adult mammalian brain (Lee et al.,
GCD and Neurogenesis: Evidence?
During neurodevelopment, new DGCs migrate from the dentate ventricular zone to the granule cell layer to form an “outside-in” dentate gyrus, where the outer-granular cells are the oldest (and showing earliest NeuN immunoreactivity), and DGCs located in the inner layer (basal granule cells) are the youngest (Altman and Bayer,
We did not detect reelin, a glycoprotein secreted by Cajal-Retzius cells to regulate the migration of DGCs during neurodevelopment, in our samples. This is confirmed in subsequent in situ hybridization studies using a probe against RELN mRNA, where no positive labeling was observed in the hippocampus of MTLE cases with GCD. This finding is consistent with previous studies that have reported low levels of RELN mRNA in MTLE patients with hippocampal sclerosis and GCD (Haas et al.,
Rho GTPases and Mechanisms for Migration or GCD
Due to the observation of Rho GTPases in the dispersed DGCs, these proteins have become the focus of further investigation as to their role in pathomechanisms underlying GCD.
The main finding in this study is the upregulation of proteins involved in the Rho GTPase signaling pathway in dispersed DGCs of patients with MTLE and GCD. Rho GTPases belong to the Rho family of GTPases, which is a subgroup of the Ras family of small GTP binding protein (Heasman and Ridley,
Other modes of cellular migration involving Rho GTPases include “frog leap” and “vessel-based” migrations. Using live imaging techniques, a study reported that 50% of the adult-born new DGCs had leading process pointed tangentially in the subgranular zone of the hippocampal granule cell layer, and these cells underwent lateral migration in small clusters coupled by connexin 43 before migrating radially into the deeper granule cell layer (Wang et al., 2019). During this migratory process, the leading cells in the migratory cluster changed repeatedly (akin to leapfrog), hovering forward and backward as the cluster moved towards their final destination. Other animal studies have also reported that gap junctions are important for neuronal dispersion in the embryonic cortex (Elias et al.,
Conclusion
In conclusion, we have shown limited evidence to support ongoing adult neurogenesis in the hippocampus of patients with MTLE, but evidence of differential dysmaturation between dispersed and basal DGCs has been shown. We have provided evidence from proteomic and immunohistochemical studies to demonstrate that DGCs contribute to ongoing structural and synaptic changes in the MTLE human brain, and expression of Rho GTPases in these cells may support abnormal cellular migratory activities that are linked to GCD pathology. Further studies are required to assess the possible contribution of DGCs expressing Rho GTPases to seizure generation and cognitive impairments.
Statements
Data availability statement
Peptide identification and quantification data analyzed in this study can be found in the Supplementary Material S9. Any further queries related to data availability should be directed to Professor MT (m.thom@ucl.ac.uk).
Ethics statement
The studies involving human participants were reviewed and approved by Epilepsy Society Brain and Tissue Bank (NRES 17/SC/0573). Informed written consents were obtained from all tissue donors.
Author contributions
JL, MT, and SS planned and designed the study. KM and this team performed the proteomics analyses. ND and BA-K conducted experiments using in situ hybridization and immunohistochemistry, respectively. JL performed bioinformatics and quantitative analyses. All authors contributed to the writing and reviewing of the manuscript.
Funding
This work was supported by Medical Research Council (MRC MR/J0127OX/1), European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement EPITARGET (#602102), and through Epilepsy Society from the Horne Family Charitable Foundation. This work was undertaken at the University of Westminster and UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. Proteomics was performed by Mills Research Group at the Biological Mass Spectrometry Centre, UCL Great Ormond Street Institute of Child Health. JL received funding from the EPITARGET (#602102), and Research Starter Fund from the University of Westminster. The Epilepsy Society Brain and Tissue Bank at UCL was funded by the Epilepsy Society.
Acknowledgments
We would like to thanks patients who donated their brain tissue to the Epilepsy Society Brain and Tissue Bank and consented for the use of their valuable tissue in research. We would like to acknowledge Houda Aljibouri for her assistance with optimizing conditions for double-label in situ hybridization and immunohistochemical experiments.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2020.00053/full#supplementary-material.
- CA
cornu ammonis
- GCD
granule cell dispersion
- GCL
granule cell layer
- HS ILAE
Type 1 hippocampal sclerosis Type 1 according to International League Against Epilepsy classification system
- MOL
molecular layer
- MTLE
Mesial Temporal Lobe Epilepsy.
Abbreviations
References
1
AbrahámH.RichterZ.GyimesiC.HorváthZ.JanszkyJ.DócziT.et al. (2011). Degree and pattern of calbindin immunoreactivity in granule cells of the dentate gyrus differ in mesial temporal sclerosis, cortical malformation- and tumor-related epilepsies. Brain Res.1399:66. 10.1016/j.brainres.2011.05.010
2
AbrahámH.VeszprémiB.KravjákA.KovácsK.GömöriÉ.SeressL. (2009). Ontogeny of calbindin immunoreactivity in the human hippocampal formation with a special emphasis on granule cells of the dentate gyrus. Int. J. Dev. Neurosci.27, 115–127. 10.1016/j.ijdevneu.2008.12.004
3
AlthausA. L.MooreS. J.ZhangH.Du PlummerX.MurphyG. G.ParentJ. M. (2019). Altered synaptic drive onto birthdated dentate granule cells in experimental temporal lobe epilepsy. J. Neurosci., 7604–7614. 10.1523/jneurosci.0654-18.2019
4
AltmanJ.BayerS. A. (1990). Mosaic organization of the hippocampal neuroepithelium and the multiple germinal sources of dentate granule cells. J. Comp. Neurol.301, 325–342. 10.1002/cne.903010302
5
ArellanoJ. I.MuozA.BallesterosYezI.SolaR. G.DeFelipeJ. (2004). Histopathology and reorganization of chandelier cells in the human epileptic sclerotic hippocampus. Brain127, 45–64. 10.1093/brain/awh004
6
BankheadP.LoughreyM. B.FernándezJ. A.DombrowskiY.McArtD. G.DunneP. D.et al. (2017). QuPath: open source software for digital pathology image analysis. Sci. Rep.7:16878. 10.1038/s41598-017-17204-5
7
BarnaJ.DiménD.PuskaG.KovácsD.CsikósV.OláhS.et al. (2019). Complement component 1q subcomponent binding protein in the brain of the rat. Sci. Rep.9:4597. 10.1038/s41598-019-40788-z
8
BegcevicI.KosanamH.Martínez-MorilloE.DimitromanolakisA.DiamandisP.KuzmanovU.et al. (2013). Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains. Clin. Proteomics10:5. 10.1186/1559-0275-10-5
9
BlümckeI.KistnerI.ClusmannH.SchrammJ.BeckerA. J.ElgerC. E.et al. (2009). Towards a clinico-pathological classification of granule cell dispersion in human mesial temporal lobe epilepsies. Acta Neuropathol.117:535. 10.1007/s00401-009-0512-5
10
BlümckeI.ScheweJ.-C.NormannS.BrüstleO.SchrammJ.ElgerC. E.et al. (2001). Increase of nestin-immunoreactive neural precursor cells in the dentate gyrus of pediatric patients with early-onset temporal lobe epilepsy. Hippocampus11, 311–321. 10.1002/hipo.1045
11
BlumckeI.SpreaficoR.HaakerG.CorasR.KobowK.BienC. G.et al. (2017). Histopathological findings in brain tissue obtained during epilepsy surgery. N. Engl. J. Med.377, 1648–1656. 10.1056/NEJMoa1703784
12
BlümckeI.ThomM.AronicaE.ArmstrongD. D.BartolomeiF.BernasconiA.et al. (2013). International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a task force report from the ILAE commission on diagnostic methods. Epilepsia54, 1315–1329. 10.1111/epi.12220
13
BrandtM. D.JessbergerS.SteinerB.KronenbergG.ReuterK.Bick-SanderA.et al. (2003). Transient calretinin expression defines early postmitotic step of neuronal differentiation in adult hippocampal neurogenesis of mice. Mol. Cell. Neurosci.24, 603–613. 10.1016/s1044-7431(03)00207-0
14
BuckmasterP. S.IngramE. A.WenX. (2009). Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci.29, 8259–8269. 10.1523/jneurosci.4179-08.2009
15
CavazosJ. E.ZhangP.QaziR.SutulaT. P. (2003). Ultrastructural features of sprouted mossy fiber synapses in kindled and kainic acid-treated rats. J. Comp. Neurol.458, 272–292. 10.1002/cne.10581
16
ChaiX.MünznerG.ZhaoS.TinnesS.KowalskiJ.HäusslerU.et al. (2014). Epilepsy-induced motility of differentiated neurons. Cereb. Cortex24, 2130–2140. 10.1093/cercor/bht067
17
ChenE. Y.TanC. M.KouY.DuanQ.WangZ.MeirellesG. V.et al. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics14, 128–128. 10.1186/1471-2105-14-128
18
CiprianiS.JourniacN.NardelliJ.VerneyC.DelezoideA.-L.GuimiotF.et al. (2017). Dynamic expression patterns of progenitor and neuron layer markers in the developing human dentate gyrus and fimbria. Cereb. Cortex27, 358–372. 10.1093/cercor/bhv223
19
CzechT.YangJ. W.CsaszarE.KapplerJ.BaumgartnerC.LubecG. (2004). Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem. Res.29, 2189–2196. 10.1007/s11064-004-7025-3
20
Da Costa NevesR. S.JardimA. P.CabocloL. O.LancellottiC.MarinhoT. F.HamadA. P.et al. (2013). Granule cell dispersion is not a predictor of surgical outcome in temporal lobe epilepsy with mesial temporal sclerosis. Clin. Neuropathol.32:24. 10.5414/np300509
21
de TisiJ.BellG. S.PeacockJ. L.McEvoyA. W.HarknessW. F.SanderJ. W.et al. (2011). The long-term outcome of adult epilepsy surgery, patterns of seizure remission and relapse: a cohort study. Lancet378, 1388–1395. 10.1016/S0140-6736(11)60890-8
22
EdgarP. F.DouglasJ. E.KnightC.CooperG. J.FaullR. L.KyddR. (1999a). Proteome map of the human hippocampus. Hippocampus9, 644–650. 10.1002/(sici)1098-1063(1999)9:6<644::aid-hipo5>3.0.co;2-s
23
EdgarP. F.SchonbergerS. J.DeanB.FaullR. L.KyddR.CooperG. J. (1999b). A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer’s disease individuals. Mol. Psychiatry4, 173–178. 10.1038/sj.mp.4000463
24
EliasL. A. B.TurmaineM.ParnavelasJ. G.KriegsteinA. R. (2010). Connexin 43 mediates the tangential to radial migratory switch in ventrally derived cortical interneurons. J. Neurosci.30, 7072–7072. 10.1523/jneurosci.5728-09.2010
25
EliasL. A. B.WangD. D.KriegsteinA. R. (2007). Gap junction adhesion is necessary for radial migration in the neocortex. Nature448, 901–907. 10.1038/nature06063
26
EngelJ.Jr. (1998). Etiology as a risk factor for medically refractory epilepsy: a case for early surgical intervention. Neurology51, 1243–1244. 10.1212/wnl.51.5.1243
27
EngelJ.McDermottM. P.WiebeS.LangfittJ. T.SternJ. M.DewarS.et al. (2012). Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA307, 922–930. 10.1001/jama.2012.220
28
EunJ.-P.ChoiH.-Y.KwakY.-G. (2004). Proteomic analysis of human cerebral cortex in epileptic patients. Exp. Mol. Med.36, 185–191. 10.1038/emm.2004.26
29
FöckingM.ChenW.-Q.DickerP.DunnM. J.LubecG.CotterD. R. (2012). Proteomic analysis of human hippocampus shows differential protein expression in the different hippocampal subfields. Proteomics12, 2477–2481. 10.1002/pmic.201200031
30
FreseC. K.MikhaylovaM.StucchiR.GautierV.LiuQ.MohammedS.et al. (2017). Quantitative map of proteome dynamics during neuronal differentiation. Cell Rep.18, 1527–1542. 10.1016/j.celrep.2017.01.025
31
FritzR. D.LetzelterM.ReimannA.MartinK.FuscoL.RitsmaL.et al. (2013). A versatile toolkit to produce sensitive FRET biosensors to visualize signaling in time and space. Sci. Signal.6, rs12–rs12. 10.1126/scisignal.2004135
32
FrotscherM. (1998). Cajal-retzius cells, Reelin and the formation of layers. Curr. Opin. Neurobiol.8, 570–575. 10.1016/s0959-4388(98)80082-2
33
FrotscherM.HaasC. A.FörsterE. (2003). Reelin controls granule cell migration in the dentate gyrus by acting on the radial glial scaffold. Cereb. Cortex13, 634–640. 10.1093/cercor/13.6.634
34
FukataY.ItohT. J.KimuraT.MénagerC.NishimuraT.ShiromizuT.et al. (2002). CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat. Cell Biol.4, 583–591. 10.1038/ncb825
35
HaasC. A.DudeckO.KirschM.HuszkaC.KannG.PollakS.et al. (2002). Role for reelin in the development of granule cell dispersion in temporal lobe epilepsy. J. Neurosci.22, 5797–5802. 10.1523/jneurosci.22-14-05797.2002
36
HaasC.FrotscherM. (2010). Reelin deficiency causes granule cell dispersion in epilepsy. Exp. Brain Res.200, 141–149. 10.1007/s00221-009-1948-5
37
HeS.WangQ.HeJ.PuH.YangW.JiJ. (2006). Proteomic analysis and comparison of the biopsy and autopsy specimen of human brain temporal lobe. Proteomics6, 4987–4996. 10.1002/pmic.200600078
38
HeasmanS. J.RidleyA. J. (2008). Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol.9, 690–701. 10.1038/nrm2476
39
HeinrichC.NittaN.FlubacherA.MüllerM.FahrnerA.KirschM.et al. (2006). Reelin deficiency and displacement of mature neurons, but not neurogenesis, underlie the formation of granule cell dispersion in the epileptic hippocampus. J. Neurosci.26, 4701–4713. 10.1523/JNEUROSCI.5516-05.2006
40
HesterM. S.DanzerS. C. (2013). Accumulation of abnormal adult-generated hippocampal granule cells predicts seizure frequency and severity. J. Neurosci.33, 8926–8936. 10.1523/jneurosci.5161-12.2013
41
HeywoodW. E.MillsP.GrunewaldS.WorthingtonV.JaekenJ.CarrenoG.et al. (2013). A new method for the rapid diagnosis of protein n-linked congenital disorders of glycosylation. J. Proteome Res.12, 3471–3479. 10.1021/pr400328g
42
HikitaT.OhnoA.SawadaM.OtaH.SawamotoK. (2014). Rac1-mediated indentation of resting neurons promotes the chain migration of new neurons in the rostral migratory stream of post-natal mouse brain. J. Neurochem.128, 790–797. 10.1111/jnc.12518
43
HondiusD. C.van NieropP.LiK. W.HoozemansJ. J. M.van der SchorsR. C.van HaastertE. S.et al. (2016). Profiling the human hippocampal proteome at all pathologic stages of Alzheimer’s disease. Alzheimers Dement.12, 654–668. 10.1016/j.jalz.2015.11.002
44
HouserC. R. (1990). Granule cell dispersion in the dentate gyrus of humans with temporal lobe epilepsy. Brain Res.535, 195–204. 10.1016/0006-8993(90)91601-c
45
Huang daW.ShermanB. T.LempickiR. A. (2009a). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res.37, 1–13. 10.1093/nar/gkn923
46
Huang daW.ShermanB. T.LempickiR. A. (2009b). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc.4, 44–57. 10.1038/nprot.2008.211
47
InagakiN.ChiharaK.ArimuraN.MénagerC.KawanoY.MatsuoN.et al. (2001). CRMP-2 induces axons in cultured hippocampal neurons. Nat. Neurosci.4, 781–782. 10.1038/90476
48
KahnJ. B.PortR. G.YueC.TakanoH.CoulterD. A. (2019). Circuit-based interventions in the dentate gyrus rescue epilepsy-associated cognitive dysfunction. Brain142, 2705–2721. 10.1093/brain/awz209
49
KanekoN.SawadaM.SawamotoK. (2017). Mechanisms of neuronal migration in the adult brain. J. Neurochem.141, 835–847. 10.1111/jnc.14002
50
KangH. J.KawasawaY. I.ChengF.ZhuY.XuX.LiM.et al. (2011). Spatio-temporal transcriptome of the human brain. Nature478, 483–489. 10.1038/nature10523
51
KelemenA.PeterH. (2010). Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr. Dis. Treat.6, 465–471. 10.2147/ndt.s7967
52
Keren-AviramG.DachetF.BaglaS.BalanK.LoebJ. A.DratzE. A. (2018). Proteomic analysis of human epileptic neocortex predicts vascular and glial changes in epileptic regions. PLoS One13:e0195639. 10.1371/journal.pone.0195639
53
KobowK.JeskeI.HildebrandtM.HaukeJ.HahnenE.BusleiR.et al. (2009). Increased reelin promoter methylation is associated with granule cell dispersion in human temporal lobe epilepsy. J. Neuropathol. Exp. Neurol.68, 356–364. 10.1097/nen.0b013e31819ba737
54
KoopmansF.PandyaN. J.FrankeS. K.PhillippensI. H. C. M. H.PaliukhovichI.LiK. W.et al. (2018). Comparative hippocampal synaptic proteomes of rodents and primates: differences in neuroplasticity-related proteins. Front. Mol. Neurosci.11:364. 10.3389/fnmol.2018.00364
55
KovacS.Dinkova KostovaA. T.HerrmannA. M.MelzerN.MeuthS. G.GorjiA. (2017). Metabolic and homeostatic changes in seizures and acquired epilepsy—mitochondria, calcium dynamics and reactive oxygen species. Int. J. Mol. Sci.18:1935. 10.3390/ijms18091935
56
Krook-MagnusonE.ArmstrongC.BuiA.LewS.OijalaM.SolteszI. (2015). In vivo evaluation of the dentate gate theory in epilepsy. J. Physiol.593, 2379–2388. 10.1113/JP270056
57
KuleshovM. V.JonesM. R.RouillardA. D.FernandezN. F.DuanQ.WangZ.et al. (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res.44:W90. 10.1093/nar/gkw377
58
LeeJ. M.HongJ.MoonG. J.JungU. J.WonS.-Y.KimS. R. (2018). Morin prevents granule cell dispersion and neurotoxicity via suppression of mTORC1 in a kainic acid-induced seizure model. Exp. Neurobiol.27, 226–237. 10.5607/en.2018.27.3.226
59
LeeC.HuJ.RallsS.KitamuraT.LohY. P.YangY.et al. (2012). The molecular profiles of neural stem cell niche in the adult subventricular zone. PLoS One7:e50501. 10.1371/journal.pone.0050501
60
LiuJ. Y. W.ReevesC.DiehlB.CoppolaA.Al-HajriA.HoskoteC.et al. (2016). Early lipofuscin accumulation in frontal lobe epilepsy. Ann. Neurol.80, 882–895. 10.1002/ana.24803
61
LiuJ.ReevesC.JacquesT.McEvoyA.MiserocchiA.ThompsonP.et al. (2018). Nestin-expressing cell types in the temporal lobe and hippocampus: morphology, differentiation and proliferative capacity. Glia66, 62–77. 10.1002/glia.23211
62
LiuJ.ReevesC.MichalakZ.CoppolaA.DiehlB.SisodiyaS. M.et al. (2014). Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies. Acta Neuropathol. Commun.2:71. 10.1186/2051-5960-2-71
63
LurtonD.El BahhB.SundstromL.RougierA. (1998). Granule cell dispersion is correlated with early epileptic events in human temporal lobe epilepsy. J. Neurol. Sci.154, 133–136. 10.1016/s0022-510x(97)00220-7
64
MaL.LiuY.-P.GengC.-Z.WangX.-L.WangY.-J.ZhangX.-H. (2010). Over expression of RhoA is associated with progression in invasive breast duct carcinoma. Breast J.16, 105–107. 10.1111/j.1524-4741.2009.00860.x
65
MaglóczkyZ.HalászP.VajdaJ.CzirjákS.FreundT. F. (1997). Loss of Calbindin-D 28K immunoreactivity from dentate granule cells in human temporal lobe epilepsy. Neuroscience76, 377–385. 10.1016/s0306-4522(96)00440-x
66
ManwaringV.HeywoodW. E.ClaytonR.LachmannR. H.KeutzerJ.HindmarshP.et al. (2013). The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric fabry and type-i diabetic patients. J. Proteome Res.12, 2013–2021. 10.1021/pr301200e
67
MartinK.ReimannA.FritzR. D.RyuH.JeonN. L.PertzO. (2016). Spatio-temporal co-ordination of RhoA, Rac1 and Cdc42 activation during prototypical edge protrusion and retraction dynamics. Sci. Rep.6:21901. 10.1038/srep21901
68
MartinianL.CatarinoC. B.ThompsonP.SisodiyaS. M.ThomM. (2012). Calbindin D28K expression in relation to granule cell dispersion, mossy fibre sprouting and memory impairment in hippocampal sclerosis: a surgical and post mortem series. Epilepsy Res.98, 14–24. 10.1016/j.eplepsyres.2011.08.011
69
MériauxC.FranckJ.ParkD. B.QuanicoJ.KimY. H.ChungC. K.et al. (2014). Human temporal lobe epilepsy analyses by tissue proteomics. Hippocampus24, 628–642. 10.1002/hipo.22246
70
MeunierB.DumasE.PiecI.BéchetD.HébraudM.HocquetteJ.-F. (2007). Assessment of hierarchical clustering methodologies for proteomic data mining. J. Proteome Res.6, 358–366. 10.1021/pr060343h
71
MilesR.WongR. K. (1983). Single neurones can initiate synchronized population discharge in the hippocampus. Nature306, 371–373. 10.1038/306371a0
72
Moreno-JiménezE. P.Flor-GarcíaM.Terreros-RoncalJ.RábanoA.CafiniF.Pallas-BazarraN.et al. (2019). Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. Nat. Med.25, 554–560. 10.1038/s41591-019-0375-9
73
MurphyB. L.DanzerS. C. (2011). Somatic translocation: a novel mechanism of granule cell dendritic dysmorphogenesis and dispersion. J. Neurosci.31, 2959–2964. 10.1523/jneurosci.3381-10.2011
74
OrcinhaC.MünznerG.GerlachJ.KiliasA.FolloM.EgertU.et al. (2016). Seizure-induced motility of differentiated dentate granule cells is prevented by the central reelin fragment. Front. Cell. Neurosci.10:183. 10.3389/fncel.2016.00183
75
OtaH.HikitaT.SawadaM.NishiokaT.MatsumotoM.KomuraM.et al. (2014). Speed control for neuronal migration in the postnatal brain by Gmip-mediated local inactivation of RhoA. Nat. Commun.5:4532. 10.1038/ncomms5532
76
Overstreet-WadicheL. S.BrombergD. A.BensenA. L.WestbrookG. L. (2006). Seizures accelerate functional integration of adult-generated granule cells. J. Neurosci.26, 4095–4103. 10.1523/jneurosci.5508-05.2006
77
ParentJ. M.ElliottR. C.PleasureS. J.BarbaroN. M.LowensteinD. H. (2006). Aberrant seizure-induced neurogenesis in experimental temporal lobe epilepsy. Ann. Neurol.59, 81–91. 10.1002/ana.20699
78
PersikeD.LimaM.AmorimR.CavalheiroE.YacubianE.CentenoR.et al. (2012). Hippocampal proteomic profile in temporal lobe epilepsy. J. Epilepsy Clin. Neurophysiol.18, 53–56. 10.1590/S1676-26492012000200007
79
PersikeD. S.Marques-CarneiroJ. E.SteinM. L. D. L.YacubianE. M. T.CentenoR.CanzianM.et al. (2018). Altered proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Pharmaceuticals11:E95. 10.3390/ph11040095
80
PomberoA.Garcia-LopezR.EstiradoA.MartinezS. (2018). Vascular pattern of the dentate gyrus is regulated by neural progenitors. Brain Struct. Funct.223, 1971–1987. 10.1007/s00429-017-1603-z
81
KoyamaR.TaoK.SasakiT.IchikawaJ.MiyamotoD.MuramatsuR.et al. (2012). GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy. Nat. Med.18, 1271–1278. 10.1038/nm.2850
82
SchaarB. T.McConnellS. K. (2005). Cytoskeletal coordination during neuronal migration. Proc. Natl. Acad. Sci. U S A102, 13652–13657. 10.1073/pnas.0506008102
83
ScharfmanH. E.MacLuskyN. J. (2014). Differential regulation of BDNF, synaptic plasticity and sprouting in the hippocampal mossy fiber pathway of male and female rats. Neuropharmacology76, 696–708. 10.1016/j.neuropharm.2013.04.029
84
SchmidtA.HallA. (2002). Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev.16, 1587–1609. 10.1101/gad.1003302
85
SeressL.ÁbrahámH.TornóczkyT.KosztolányiG. (2001). Cell formation in the human hippocampal formation from mid-gestation to the late postnatal period. Neuroscience105, 831–843. 10.1016/s0306-4522(01)00156-7
86
ShaL.-Z.XingX.-L.ZhangD.YaoY.DouW.-C.JinL.-R.et al. (2012). Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy. PLoS One7:e39152. 10.1371/journal.pone.0039152
87
ShinoharaR.ThumkeoD.KamijoH.KanekoN.SawamotoK.WatanabeK.et al. (2012). A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors. Nat. Neurosci.15, 373–380. 10.1038/nn.3020
88
SoleckiD. J.TrivediN.GovekE.-E.KerekesR. A.GleasonS. S.HattenM. E. (2009). Myosin II motors and F-actin dynamics drive the coordinated movement of the centrosome and soma during CNS glial-guided neuronal migration. Neuron63, 63–80. 10.1016/j.neuron.2009.05.028
89
SorrellsS. F.ParedesM. F.Cebrian-SillaA.SandovalK.QiD.KelleyK. W.et al. (2018). Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature555, 377–381. 10.1038/nature25975
90
SosunovA. A.WuX.McGovernR. A.CoughlinD. G.MikellC. B.GoodmanR. R.et al. (2012). The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia53, 78–86. 10.1111/j.1528-1167.2012.03478.x
91
SultanaR.Boyd-KimballD.CaiJ.PierceW. M.KleinJ. B.MerchantM.et al. (2007). Proteomics analysis of the Alzheimer’s disease hippocampal proteome. J. Alzheimers Dis.11, 153–164. 10.3233/jad-2007-11203
92
SunG. J.ZhouY.StadelR. P.MossJ.YongJ. H. A.ItoS.et al. (2015). Tangential migration of neuronal precursors of glutamatergic neurons in the adult mammalian brain. Proc. Natl. Acad. Sci. U S A112, 9484–9489. 10.1073/pnas.1508545112
93
SutulaT.CascinoG.CavazosJ.ParadaI.RamirezL. (1989). Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann. Neurol.26, 321–330. 10.1002/ana.410260303
94
ThomM.LiagkourasI.ElliotK. J.MartinianL.HarknessW.McEvoyA.et al. (2010). Reliability of patterns of hippocampal sclerosis as predictors of postsurgical outcome. Epilepsia51, 1801–1808. 10.1111/j.1528-1167.2010.02681.x
95
ThomM.LiagkourasI.MartinianL.LiuJ.CatarinoC. B.SisodiyaS. M. (2012). Variability of sclerosis along the longitudinal hippocampal axis in epilepsy: a post mortem study. Epilepsy Res.102, 45–59. 10.1016/j.eplepsyres.2012.04.015
96
ThomM.MartinianL.WilliamsG.StoeberK.SisodiyaS. M. (2005). Cell proliferation and granule cell dispersion in human hippocampal sclerosis. J. Neuropathol. Exp. Neurol.64, 194–201. 10.1093/jnen/64.3.194
97
WangJ.ShenJ.KirschenG. W.GuY.JessbergerS.GeS. (2019). Lateral dispersion is required for circuit integration of newly generated dentate granule cells. Nat. Commun.10:3324. 10.1038/s41467-019-11206-9
98
WieserH.-G.ILAE Commission on Neurosurgery of Epilepsy. (2004). ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia45, 695–714. 10.1111/j.0013-9580.2004.09004.x
99
YangJ. W.CzechT.FelizardoM.BaumgartnerC.LubecG. (2006). Aberrant expression of cytoskeleton proteins in hippocampus from patients with mesial temporal lobe epilepsy. Amino Acids30, 477–493. 10.1007/s00726-005-0281-y
100
YangJ. W.CzechT.LubecG. (2004a). Proteomic profiling of human hippocampus. Electrophoresis25, 1169–1174. 10.1002/elps.200305809
101
YangJ. W.CzechT.YamadaJ.CsaszarE.BaumgartnerC.SlavcI.et al. (2004b). Aberrant cytosolic acyl-CoA thioester hydrolase in hippocampus of patients with mesial temporal lobe epilepsy. Amino Acids27, 269–275. 10.1007/s00726-004-0138-9
102
YuY.-C.HeS.ChenS.FuY.BrownK. N.YaoX.-H.et al. (2012). Preferential electrical coupling regulates neocortical lineage-dependent microcircuit assembly. Nature486, 113–117. 10.1038/nature10958
103
ZarcoN.NortonE.Quiñones-HinojosaA.Guerrero-CázaresH. (2019). Overlapping migratory mechanisms between neural progenitor cells and brain tumor stem cells. Cell. Mol. Life Sci.76, 3553–3570. 10.1007/s00018-019-03149-7
104
ZhanR.TimofeevaO.NadlerJ. V. (2010). High ratio of synaptic excitation to synaptic inhibition in hilar ectopic granule cells of pilocarpine-treated rats. J. Neurophysiol.104, 3293–3304.
Summary
Keywords
proteome, dentate gyrus, epilepsy, Rho GTPases, migration
Citation
Liu JYW, Dzurova N, Al-Kaaby B, Mills K, Sisodiya SM and Thom M (2020) Granule Cell Dispersion in Human Temporal Lobe Epilepsy: Proteomics Investigation of Neurodevelopmental Migratory Pathways. Front. Cell. Neurosci. 14:53. doi: 10.3389/fncel.2020.00053
Received
30 October 2019
Accepted
21 February 2020
Published
17 March 2020
Volume
14 - 2020
Edited by
Eleonora Aronica, Amsterdam University Medical Center, Netherlands
Reviewed by
Sang Ryong Kim, Kyungpook National University, South Korea; Angelika Mühlebner, Academic Medical Center, Netherlands
Updates

Check for updates
Copyright
© 2020 Liu, Dzurova, Al-Kaaby, Mills, Sisodiya and Thom.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Thom m.thom@ucl.ac.uk
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.